Search
Colistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalCyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.
Fenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSuch capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. … In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.
Uridine triacetate
go.drugbank.com/drugs/DB09144ApprovedAdditionally, orotic acid from the de novo pyrimidine pathway that cannot be converted to UMP is excreted in the urine, accounting for the common name of the disorder, orotic aciduria. … It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself.
Dabigatran
go.drugbank.com/drugs/DB14726ApprovedInvestigationalDabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].
Nedocromil
go.drugbank.com/drugs/DB00716ApprovedA pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Pentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawnPentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in com...
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigationalHowever, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalIt is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical